JATIN PATEL
Pharmacy at Georges Rd, New Brunswick, NJ
License number
New Jersey 28RI02764900
Category
Pharmacy
Type
Pharmacist
Address
Address
2
841 Georges Rd, New Brunswick, NJ 08902
102 Timberhill Dr, Franklin Park, NJ 08823
102 Timberhill Dr, Franklin Park, NJ 08823
Phone
(732) 545-9487
(732) 545-2326 (Fax)
(732) 422-7288
(732) 545-2326 (Fax)
(732) 422-7288
Professional information
Jatin Patel - North Brunswick, NJ
Work:
First Tennessee Bank - Memphis, TN
QA /BA Analyst Product Development Indiabulls Securities LTD
Jr. Business Analyst
QA /BA Analyst Product Development Indiabulls Securities LTD
Jr. Business Analyst
Education:
ICFAI
MBA in Corporate Finance Veer Narmad South Gujarat University - Gujarat, IN
BBA in Finance
MBA in Corporate Finance Veer Narmad South Gujarat University - Gujarat, IN
BBA in Finance
Pharmaceutical Formulations Containing An Sglt2 Inhibitor
US Patent:
2013012, May 23, 2013
Filed:
Jan 4, 2013
Appl. No.:
13/734655
Inventors:
Bristol-Myers Squibb Company - Princeton NJ, US
Mandar V. Dali - Bridgewater NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Mandar V. Dali - Bridgewater NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Assignee:
BRISTOL-MYERS SQUIBB COMPANY - Princeton NJ
International Classification:
A61K 31/70
US Classification:
424452, 514 23, 424465
Abstract:
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrateand a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
Pharmaceutical Formulations Containing An Sglt2 Inhibitor
US Patent:
7851502, Dec 14, 2010
Filed:
Mar 21, 2008
Appl. No.:
12/053442
Inventors:
Dilbir S. Bindra - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/351, A61P 3/10
US Classification:
514460, 424451
Abstract:
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate.
Pharmaceutical Formulations Containing An Sglt2 Inhibitor
US Patent:
8361972, Jan 29, 2013
Filed:
Jun 21, 2012
Appl. No.:
13/529463
Inventors:
Dilbir S. Bindra - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Assignee:
Bristol Myers-Squibb Company - Princeton NJ
International Classification:
A61K 9/48, A61K 31/70, A61K 9/30, A61P 3/00, A61P 9/00
US Classification:
514 23, 424452, 424465, 424451, 514460
Abstract:
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate.
Pharmaceutical Formulations Containing An Sglt2 Inhibitor
US Patent:
8221786, Jul 17, 2012
Filed:
Nov 18, 2010
Appl. No.:
12/949473
Inventors:
Dilbir S. Bindra - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Mandar V. Dali - New Brunswick NJ, US
Prakash V. Parab - New Brunswick NJ, US
Jatin M. Patel - New Brunswick NJ, US
Li Tao - New Brunswick NJ, US
Ravindra W. Tejwani - New Brunswick NJ, US
Nipa Vatsaraj - New Brunswick NJ, US
Yongmei Wu - New Brunswick NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 9/48, A61K 31/70, A61K 9/30, A61P 3/00, A61P 9/00
US Classification:
424452, 514 23, 514460, 424465, 424451
Abstract:
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate.